REG - LungLife AI, INC - Block Listing Application

LungLife AIAnnouncement

10/11/2021 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211110:nRSJ8564Ra&default-theme=true

RNS Number : 8564R  LungLife AI, INC  10 November 2021

LungLife AI, Inc.

("LungLife" or the "Company")

 

Block Listing Application

 

LungLife AI (AIM: LLAI), the developer of clinical diagnostic solutions for
lung cancer enhanced by artificial intelligence, announces that a block
listing application (the "Block Admission") has been made to the London Stock
Exchange for up to 1,356,139 common shares of US $0.0001 each (the "Block
Listing Shares") to be admitted to trading on AIM ("Admission").

 

The common shares that are being reserved under this block listing application
will be issued by the Company, as required, in order to satisfy the exercise
of share options and vested awards pursuant to the terms of the following
share plans (the "Schemes"):

 

 Scheme                                 No. of common shares under

block listing application
 2010 Stock Incentive Plan              480,775
 2020 Stock Incentive Plan              201,374
 2021 Omnibus Long-Term Incentive Plan  673,990

 

The Block Listing Shares will, upon issue, rank equally with all other common
shares of US $0.0001 each in the capital of the Company that are then in
issue. The Block Listing Admission is expected to become effective on 15
November 2021.

 

For further information please contact:

 

 LungLife AI, Inc.                                   www.lunglifeai.com (https://www.lunglifeai.com/)
 Paul Pagano, CEO                                    Via Walbrook PR
 David Anderson, CFO

 Investec Bank plc (Nominated Adviser & Broker)      Tel: +44 (0)20 7597 5970
 Daniel Adams / Virginia Bull / Cameron MacRitchie

 Walbrook PR Limited                                  Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
                                                     (mailto:LungLifeAI@walbrookpr.com)
 Paul McManus / Alice Woodings                       Mob: 07980 541 893 / 07407 804 654

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ALSFSLFWUEFSEFF